1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

LCTX.TA
Lineage Cell Therapeutics, Inc.IL flagTel Aviv Stock Exchange
399.80
ILA
-11.70
- -
996.69MMarket Cap
Lineage Cell Therapeutics, Inc.
LCTX.TA
(Tel Aviv Stock Exchange)

Recent

price

399.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.03
0.04
0.03
0.05
0.03
0.03
0.02
0.02
0.01
0.01
0.01
0.02
0.09
0.05
0.05
0.06
0.06
Revenue per Share
-0.28
-0.35
-0.44
-0.81
-0.55
-0.59
0.34
-0.17
-0.36
-0.08
-0.14
-0.26
-0.15
-0.12
-0.09
-0.28
-0.27
Basic EPS, GAAP
-0.2
-0.31
-0.41
-0.59
-0.6
-0.63
-0.46
-0.28
-0.27
-0.22
-0.13
-0.15
- -
-0.17
-0.12
-0.08
-0.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.59
0.74
0.36
1.06
0.79
0.55
1.25
1.42
0.73
0.78
0.67
0.59
0.45
0.39
0.41
0.21
0.25
Book Value per Share
0.85
0.49
0.08
-0.07
0.31
0.54
1.24
1.37
0.7
0.36
0.25
0.2
0.09
0.03
0.1
- -
0.04
Tangible Book Value per Share
40
47
49
54
66
80
97
114
127
146
150
165
170
173
200
230
234
Basic Weighted Avg Shares
1
2
2
3
2
3
2
2
1
1
1
4
15
9
9
15
15
Sales/Revenue/Turnover
-718.25
-1,120.98
-1,476.82
-1,346.63
-2,603.08
-2,597.04
-2,618.43
-2,268.75
-2,895.13
-2,630.31
-3,421.35
-1,263.12
-153.17
-276.5
-226.11
-149.62
-154.73
Operating Margin (%)
1
2
3
4
8
6
5
3
3
3
2
1
1
1
1
1
1
Depreciation Expense
-11
-17
-21
-44
-36
-47
34
-20
-46
-12
-21
-43
-26
-21
-19
-64
-64
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-815.39
-990.74
-1,265.64
-1,533.83
-1,870.16
-1,854.42
1,490.76
-1,114.73
-3,247.88
-792.22
-2,671.28
-1,104.18
-178.69
-240.2
-195.9
-436.47
-434.44
Profit Margin (%)
33
22
3
1
25
35
17
36
30
51
36
64
41
20
37
48
48
Working Capital
- -
- -
- -
- -
- -
5
3
1
2
4
3
2
3
2
1
2
2
LT Debt
49
41
24
42
63
76
131
164
92
111
95
91
72
62
77
43
53
Total Equity
- -
- -
- -
- -
- -
- -
-54.59
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
40.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-81.47
-116.09
-66.16
-98
40.54
-14.08
-36.13
-11.36
-19.34
-43.61
-30.14
-29.97
-25.19
-97.95
-92.02
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
230
243
249
Market Capitalization
40,996
36,596
35,854

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
42
59
56
Cash, Cash Equivalents & STI
40
56
53
Accounts Receivable, Net
- -
1
1
Inventories
- -
- -
- -
Total Current Liabilities
9
11
8
Payables & Accruals
2
3
3
ST Debt
1
1
1
Deferred Revenue
4
3
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.02%
-11.73%
-43.72%
Free Cash Flow
-482.11%
-949.06%
-17.82%
Net Income, GAAP
8.03%
55.84%
241.41%
Sales/Revenue/Turnover
60.58%
140.33%
53.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
4
3
9
2025
2
3
4
7
15
2026
2
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.03
-0.02
- -
-0.09
2025
-0.02
-0.13
-0.13
- -
-0.28
2026
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
MYND Life Sciences Inc. (MYND.CN)
Core One Labs Inc. (COOL.CN)
Filana Therapeutics, Inc. (FLNA)
Hepion Pharmaceuticals, Inc. (HEPA)
HCW Biologics Inc. (HCWB)
Business
Lineage Cell Therapeutics, Inc. (LCTX) is a clinical-stage biotechnology company that develops novel allogeneic off-the-shelf cell therapies for serious neurological and ophthalmic conditions using its proprietary cell-based platform to manufacture specialized terminally differentiated human cells from pluripotent and progenitor starting materials. The company offers five key product candidates including OpRegen a retinal pigment epithelium transplant therapy for dry age-related macular degeneration under worldwide collaboration with Genentech a member of the Roche Group OPC1 an oligodendrocyte progenitor cell therapy for acute spinal cord injuries in Phase 1/2a development partially funded by the California Institute for Regenerative Medicine VAC2 an allogeneic dendritic cell immunotherapy from its VAC platform for non-small cell lung cancer in Phase 1 funded by Cancer Research UK ANP1 an auditory neuronal progenitor cell therapy for auditory neuropathy in preclinical development and PNC1 a photoreceptor neural cell therapy for vision loss due to photoreceptor dysfunction also in preclinical stages. Founded in 1990 and headquartered in Carlsbad California with operations including GMP manufacturing in Israel and R&D facilities in the United States Lineage conducts its activities primarily in North America Europe and Asia targeting patients with degenerative diseases traumatic injuries and cancers. Recent developments include registered direct offerings raising 30 million dollars across tranches in November 2024 and January 2025 extending cash runway into Q2 2027 alongside potential additional 36 million dollars from milestone-linked warrants a strategic partnership with WuXi Dai Torus providing up to 12 million dollars positive 36-month Phase 1/2a data for RG6501 OpRegen featured at Clinical Trials on the Summit 2025 ongoing efforts for CIRM grant funding for OPC1 and manufacturing advancements enabling millions of xeno-free doses to support clinical expansion.